Risk prediction in early childhood sonic hedgehog medulloblastoma treated with radiation-avoiding chemotherapy: Evidence for more than 2 subgroups.
DNA methylation profiling
Medulloblastoma
Risk prediction
Sonic hedgehog-activated
Journal
Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420
Informations de publication
Date de publication:
03 08 2023
03 08 2023
Historique:
pmc-release:
30
01
2024
medline:
4
8
2023
pubmed:
31
1
2023
entrez:
30
1
2023
Statut:
ppublish
Résumé
The prognostic impact of clinical risk factors and DNA methylation patterns in sonic hedgehog (SHH)-activated early childhood desmoplastic/nodular medulloblastoma (DMB) or medulloblastoma with extensive nodularity (MBEN) were evaluated to better identify patients at risk for relapse. One hundred and forty-four patients with DMB (n = 99) or MBEN (n = 45) aged <5 years and treated with radiation-sparing approaches, including intraventricular methotrexate in 132 patients were evaluated. Patients with DMB had less favorable 5-year progression-free survival than MBEN (5y-PFS, 71% [DMB] vs. 93% [MBEN]). Patients aged >3 years were associated with more unfavorable 5y-PFS (47% [>3 years] vs. 85% [<1 year] vs. 84% [1-3 years]). DNA methylation profiles available (n = 78) were reclassified according to the 2021 WHO classification into SHH-1 (n = 39), SHH-2 (n = 38), and SHH-3 (n = 1). Hierarchical clustering delineated 2 subgroups among SHH-2: SHH-2a (n = 19) and SHH-2b (n = 19). Patients with SHH-2b medulloblastoma were older, predominantly displayed DMB histology, and were more often located in the cerebellar hemispheres. Chromosome 9q losses were more frequent in SHH-2b, while few chromosomal alterations were observed in SHH-2a. SHH-2b medulloblastoma carried a significantly increased relapse risk (5y-PFS: 58% [SHH-2b] vs. 83% [SHH-1] vs. 95% [SHH-2a]). Subclassification of SHH-2 with key clinical and cytogenetic characteristics was confirmed using 2 independent cohorts (total n = 188). Gene mutation analysis revealed a correlation of SHH-2a with SMO mutations. These data suggest further heterogeneity within early childhood SHH-DMB/MBEN: SHH-2 splits into a very low-risk group SHH-2a enriched for MBEN histology and SMO mutations, and SHH-2b comprising older DMB patients with a higher risk of relapse.
Sections du résumé
BACKGROUND
The prognostic impact of clinical risk factors and DNA methylation patterns in sonic hedgehog (SHH)-activated early childhood desmoplastic/nodular medulloblastoma (DMB) or medulloblastoma with extensive nodularity (MBEN) were evaluated to better identify patients at risk for relapse.
METHODS
One hundred and forty-four patients with DMB (n = 99) or MBEN (n = 45) aged <5 years and treated with radiation-sparing approaches, including intraventricular methotrexate in 132 patients were evaluated.
RESULTS
Patients with DMB had less favorable 5-year progression-free survival than MBEN (5y-PFS, 71% [DMB] vs. 93% [MBEN]). Patients aged >3 years were associated with more unfavorable 5y-PFS (47% [>3 years] vs. 85% [<1 year] vs. 84% [1-3 years]). DNA methylation profiles available (n = 78) were reclassified according to the 2021 WHO classification into SHH-1 (n = 39), SHH-2 (n = 38), and SHH-3 (n = 1). Hierarchical clustering delineated 2 subgroups among SHH-2: SHH-2a (n = 19) and SHH-2b (n = 19). Patients with SHH-2b medulloblastoma were older, predominantly displayed DMB histology, and were more often located in the cerebellar hemispheres. Chromosome 9q losses were more frequent in SHH-2b, while few chromosomal alterations were observed in SHH-2a. SHH-2b medulloblastoma carried a significantly increased relapse risk (5y-PFS: 58% [SHH-2b] vs. 83% [SHH-1] vs. 95% [SHH-2a]). Subclassification of SHH-2 with key clinical and cytogenetic characteristics was confirmed using 2 independent cohorts (total n = 188). Gene mutation analysis revealed a correlation of SHH-2a with SMO mutations.
CONCLUSIONS
These data suggest further heterogeneity within early childhood SHH-DMB/MBEN: SHH-2 splits into a very low-risk group SHH-2a enriched for MBEN histology and SMO mutations, and SHH-2b comprising older DMB patients with a higher risk of relapse.
Identifiants
pubmed: 36715306
pii: 7008992
doi: 10.1093/neuonc/noad027
pmc: PMC10398808
doi:
Substances chimiques
Hedgehog Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1518-1529Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Bioinformatics. 2014 May 15;30(10):1363-9
pubmed: 24478339
Nat Rev Dis Primers. 2019 Feb 14;5(1):11
pubmed: 30765705
Epigenetics Chromatin. 2015 Jan 27;8:6
pubmed: 25972926
Lancet Oncol. 2017 Jul;18(7):958-971
pubmed: 28545823
Acta Neuropathol. 2014 Jul;128(1):137-49
pubmed: 24791927
Eur J Hum Genet. 2018 Mar;26(3):440-444
pubmed: 29302048
N Engl J Med. 2005 Mar 10;352(10):978-86
pubmed: 15758008
J Clin Oncol. 2012 Sep 10;30(26):3181-6
pubmed: 22851568
Neuro Oncol. 2011 Jun;13(6):669-79
pubmed: 21636711
Lancet Oncol. 2018 Jun;19(6):785-798
pubmed: 29753700
Cancer. 2011 Jul 15;117(14):3262-7
pubmed: 21246528
Neuro Oncol. 2020 Dec 18;22(12):1862-1872
pubmed: 32304218
J Clin Oncol. 2020 Jun 20;38(18):2028-2040
pubmed: 32330099
Cancer Cell. 2017 Jun 12;31(6):737-754.e6
pubmed: 28609654
Acta Neuropathol. 2019 Jun;137(6):1003-1015
pubmed: 30826918
Pediatr Neurol. 2015 Jul;53(1):31-46
pubmed: 26092413
Lancet Oncol. 2018 Jun;19(6):768-784
pubmed: 29778738
Neuropathol Appl Neurobiol. 2021 Feb;47(2):236-250
pubmed: 32779246
J Clin Oncol. 2021 Mar 1;39(7):822-835
pubmed: 33405951
J Clin Oncol. 2010 Nov 20;28(33):4961-8
pubmed: 20940197
J Clin Oncol. 2020 Jan 20;38(3):223-231
pubmed: 31774708
Front Oncol. 2021 Nov 23;11:756025
pubmed: 34888241
Nature. 2018 Mar 22;555(7697):469-474
pubmed: 29539639
Bioinformatics. 2016 Sep 15;32(18):2847-9
pubmed: 27207943
Nucleic Acids Res. 2013 Apr;41(7):e90
pubmed: 23476028
Bioinformatics. 2017 Feb 15;33(4):558-560
pubmed: 28035024
Nat Commun. 2021 Mar 19;12(1):1749
pubmed: 33741928
Acta Neuropathol. 2016 Jun;131(6):903-10
pubmed: 26671409
Clin Cancer Res. 2017 Jun 15;23(12):e62-e67
pubmed: 28620006
Br J Neurosurg. 1991;5(6):643-6
pubmed: 1772613